Sign inCreate account

Report workspace tools

NCT04225221COMPLETEDanonymous

Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design

Sponsor

Source record

University of North Carolina, Chapel Hill

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Bulimia Nervosa

Indication / condition

AI-normalized

Bulimia Nervosa

Intervention

Source record

Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule

Source & freshness

Source record

NCT ID

NCT04225221

Original source

ClinicalTrials.gov

Source last updated

Jul 26, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04225221

Title

Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design

Sponsor

University of North Carolina, Chapel Hill

Status

COMPLETED

Phase

Phase 2

Condition raw

Bulimia Nervosa

Condition normalized

Bulimia Nervosa

Modality raw

Bulimia Nervosa

Modality normalized

small molecule

Target raw

Bulimia Nervosa

Target normalized

Bulimia Nervosa

Interventions

Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule

Public preview

Source record

This clinical trial investigates the effects of ovarian hormones, specifically estradiol and progesterone, on binge eating behaviors in women diagnosed with bulimia nervosa. The study aims to elucidate the neurobiological mechanisms underlying binge eating and hormone interactions, potentially leading to novel pharmacological treatments for bulimia nervosa.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04225221

Status

COMPLETED

Phase

Phase 2

Sponsor

University of North Carolina, Chapel Hill

Executive brief

Investment-Ready Snapshot

This clinical trial investigates the effects of ovarian hormones, specifically estradiol and progesterone, on binge eating behaviors in women diagnosed with bulimia nervosa. The study aims to elucidate the neurobiological mechanisms underlying binge eating and hormone interactions, potentially leading to novel pharmacological treatments for bulimia nervosa.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 26, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04225221

Indication

Bulimia Nervosa

Modality

small molecule

Target

Bulimia Nervosa

Intervention

Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.